Should You Sell Neurosense Therapeutics Ltd (NRSN) Stock Tuesday Morning?

Neurosense Therapeutics Ltd (NRSN) is lower by Tuesday morning, with the stock losing -5.21% in pre-market trading to 2. NRSN's short-term technical score of 61 indicates that the stock has traded more bullishly over the last month than 61% of stocks on the market. In the Biotechnology industry, which ranks 90 out of 146 industries, NRSN ranks higher than 70% of stocks. Neurosense Therapeutics Ltd has risen 64.84% over the past month, closing at $1.28 on February 6. During this period of time, the stock fell as low as $1.25 and as high as $2.33. NRSN has an average analyst recommendation of Strong Buy. The company has an average price target of $5.25.

NRSN has an Overall Score of 80. Find out what this means to you and get the rest of the rankings on NRSN!

See Full NRSN Report

Neurosense Therapeutics Ltd has a Long-Term Technical rank of 99. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 1% of the market scoring higher. In the Biotechnology industry which is number 46 by this metric, NRSN ranks better than 46% of stocks.

Important Dates for Investors in NRSN:

-Neurosense Therapeutics Ltd is set to release earnings on 2024-03-27. Over the last 12 months, the company has reported EPS of $-0.94. -We do not have a set dividend date for Neurosense Therapeutics Ltd at this time. Click Here To Get The Full Report on Neurosense Therapeutics Ltd (NRSN)